White Paper · Cannabis & Hemp · Illinois & Missouri

Cannabis & Hemp Compliance in Illinois & Missouri: The 2026 Operator’s Guide

In 2026 a cannabis or hemp operator has to reconcile a partial federal rescheduling, a two-step change to the federal hemp definition, a new Illinois Hemp Act, a Missouri law that treats intoxicating hemp as marijuana, and two state licensing systems. This paper sorts those rules by product, state and license.

By Lincoln Square Law · 12-minute read

Build the compliance map by product, state and license

A cannabis or hemp operator should start every compliance question with three coordinates: the product, the jurisdiction and the license that authorizes the activity. Federal law answers classification questions under the Controlled Substances Act and the federal hemp definition. Illinois and Missouri decide who may conduct state-authorized activity and under what operating rules.

In Illinois, adult-use cannabis is regulated under the Cannabis Regulation and Tax Act (410 ILCS 705), and the medical program continues under the Compassionate Use of Medical Cannabis Program Act (410 ILCS 130). Public Act 104-0463 adds the Illinois Hemp Act. Missouri’s medical and adult-use programs arise under Article XIV of the Missouri Constitution and the Division of Cannabis Regulation’s rules at 19 CSR 100-1 (Mo. Const. art. XIV, secs. 1 and 2).

A company should therefore not carry one generic “cannabis compliant” status. A better matrix lists each site, license, activity, product category and state, then adds the federal classification, so the company can tell whether a contemplated manufacture, sale, advertisement or transaction is authorized before it acts.

Federal marijuana scheduling changed, but only for defined medical activity

On April 28, 2026, the Acting Attorney General issued a final rule, effective the same day, that moved two categories of marijuana to Schedule III: drug products containing marijuana that FDA has approved, and marijuana, marijuana extract and naturally derived delta-9 THC subject to a state medical marijuana license (91 Fed. Reg. 22714, 21 C.F.R. 1308.13(g)). The rule states that any other form of marijuana remains a Schedule I controlled substance. Adult-use marijuana is therefore still in Schedule I under federal law.

Schedule III status comes with federal registration. The rule created an expedited process for state medical licensees seeking DEA registration as manufacturers, distributors or dispensers, limited to medical purposes (21 C.F.R. 1301.13(k)). According to the rule, an applicant that filed within 60 days after publication may continue state-licensed medical activity while its application is pending. An operator that missed that window should confirm its federal position before relying on the rescheduling.

Section 280E denies deductions and credits to a business that consists of trafficking in Schedule I or II substances (26 U.S.C. 280E). The rule states that holders of state medical marijuana licenses will no longer be subject to that disallowance, but also that nothing in the rule determines federal tax liability. Adult-use revenue remains outside the rule, so a company with both medical and adult-use activity has to be able to show which inventory, sales and costs belong to which license.

Broader rescheduling is a separate proceeding. On the same day, DEA gave notice of a hearing beginning June 29, 2026 on the 2024 proposal to move marijuana generally to Schedule III (91 Fed. Reg. 22777). As of this writing, no final rule from that proceeding has appeared in the Federal Register.

Illinois dispensaries and the medical license after SB 3222

The Public Act that created the Illinois Hemp Act also amended the cannabis statutes, mostly effective on signing, June 12, 2026. According to IDFPR, beginning September 10, 2026, an adult-use dispensary in good standing may opt in to a medical dispensary license and sell to medical cannabis patients at the medical tax rate. IDFPR also states that the law prevents a dispensary from separating its adult-use license from its medical license, in the facility or in the ownership structure (IDFPR, SB3222 Fact Sheet).

Read beside the federal rule, the opt-in is not only a state tax question. Marijuana subject to a state medical marijuana license is now in Schedule III, while the same dispensary’s adult-use sales remain in Schedule I. We recommend deciding, before applying, how the dispensary will identify medical inventory and sales, whether it will seek DEA registration, and how its seed-to-sale records will support the separation.

The federal hemp definition is changing in stages

Public Law 119-37, enacted November 12, 2025, rewrote the federal hemp definition in section 297A of the Agricultural Marketing Act of 1946. The amended text measures total tetrahydrocannabinols, including THCA, against the 0.3 percent dry-weight limit. It excludes products containing cannabinoids the plant cannot naturally produce, or that were synthesized or manufactured outside the plant. It also excludes final hemp-derived cannabinoid products with more than 0.4 milligrams combined total per container of total THC and other cannabinoids HHS determines have similar effects, with “container” meaning the innermost packaging touching the product. The amendments take effect 365 days after enactment, November 12, 2026 (Pub. L. 119-37, div. B, sec. 781, 7 U.S.C. 1639o).

Public Law 119-103, approved September 2, 2026, then narrowed the first month. Until December 11, 2026, the section 781 amendments apply only to intermediate and final products containing cannabinoids that are not capable of being naturally produced by Cannabis sativa L., the products in paragraphs (1)(C)(ii)(I) and (1)(C)(iv)(I) (Pub. L. 119-103, div. B, sec. 2019). Under current law, the broader tests apply after that date.

Classify actual SKUs and ingredients under each phase, and keep cannabinoid identity, production method, total-THC data, intermediate or final status and container configuration in the product file. A certificate of analysis that reports only delta-9 THC does not answer the amended statute’s questions. Our white paper on the November 12 and December 11 federal hemp transition works through both phases in detail.

Illinois hemp becomes its own regulated operating system

Public Act 104-0463 (SB 3222), approved June 12, 2026, creates the Illinois Hemp Act under the Department of Agriculture. The Act defines hemp by a total tetrahydrocannabinol concentration of not more than 0.3 percent on a dry-weight basis and limits a final consumer hemp cannabinoid product to 0.4 milligrams of total tetrahydrocannabinols per container. It creates a hemp cultivation license, an industrial hemp processor registration and a hemp product manufacturer license. Final consumer products may not contain alcoholic liquor, tobacco or nicotine and may not be intended to be smoked or vaped (P.A. 104-0463, secs. 5, 35).

The timing comes in two steps. The Department’s bulletin states that, effective immediately on June 12, products containing more than 0.4 milligrams of THC, or of other cannabinoids with similar effects, may be offered for sale only to individuals over age 21, and that hemp products must meet labeling requirements. On November 12, 2026, the Industrial Hemp Act (505 ILCS 89) is repealed and replaced by the Illinois Hemp Act, and existing hemp cultivation licenses transfer to the new Act (Ill. Dep’t of Agriculture, IB-2026-06).

Section 10 of the Act sets the gate. No person may distribute or sell cannabis, hemp, industrial hemp or a product derived from them in Illinois except as the cannabis statutes or the Hemp Act authorize, unless the product meets the definition of a final consumer hemp cannabinoid product or an industrial hemp product (P.A. 104-0463, sec. 10). A product can satisfy the federal definition and still fail the Illinois category, license, label or testing requirements, so supply and manufacturing contracts should assign each state obligation. Our hemp product compliance worksheet lists the label and packaging items SKU by SKU.

Missouri cannabis compliance remains license-centered

Article XIV authorizes Missouri’s medical and adult-use programs and places regulatory authority in the Department of Health and Senior Services (Mo. Const. art. XIV, secs. 1 and 2). The Division of Cannabis Regulation’s rules are consolidated in 19 CSR 100-1, which the Division lists as effective May 30, 2026, and cover licensing, ownership, security, testing, packaging, seed-to-sale tracking, transportation and each facility type.

Work from the current rule set and track changes separately. As of this writing, the Division lists an emergency amendment to 19 CSR 100-1.070 on criminal history review for agent identification card applicants, effective September 30, 2026, and a proposed amendment to 19 CSR 100-1.180 on curbside pickup, with comments accepted from September 1 to October 1, 2026. A proposed rule is not current law until adopted, so date the source set behind each procedure.

Transactions need the same discipline. The Missouri Constitution bars a licensed facility from transferring its license without the Department’s express consent, and the rules separately govern facility ownership (Mo. Const. art. XIV, sec. 2, 19 CSR 100-1.070). A purchase, investment or management agreement should make the approval a condition, name who files and prevent closing before approval issues. Our paper on social-equity and microbusiness ownership covers the ownership rules.

Missouri moves intoxicating hemp into the marijuana system

Missouri took a different route. House Bill 2641 establishes the Intoxicating Cannabinoid Control Act, which, according to the Division’s guidance, makes intoxicating hemp-derived cannabinoid products marijuana as defined in Article XIV, with a limited exception that depends on federal action. Licensees may acquire and sell, from outside sources, hemp-derived cannabinoids with no more than 0.3 percent total THC or products with no more than 0.4 milligrams total THC. Anything above those limits is marijuana requiring Article XIV licensure. Synthetic cannabinoids, and cannabinoids produced by chemical conversion of other cannabinoids, remain prohibited for licensees (Mo. DHSS, Missouri House Bill 2641 Guidance).

The dates track the federal transition. The House summary of the passed bill states that the hemp provisions take effect November 12, 2026, and that for some products they apply only while federal hemp restrictions are in effect if Congress delays them. The Division’s guidance adds that beverages with naturally occurring cannabinoids not synthesized or manufactured outside the plant are not subject to Article XIV until December 11, 2026, if not sold to anyone under 21. A hemp brand selling into Missouri should decide whether to exit, reformulate within the limits or sell through licensed facilities.

Use one control framework with state-specific overlays

A multi-state operator does not need separate compliance systems, but it does need jurisdiction-specific controls. The common layer covers license inventory, training, incident escalation, vendor diligence, change control, records retention and product-release approval. Each state overlay states the actual requirement, form, deadline and regulator. The product record should connect formulation, testing, labeling, packaging and approved claims, and any change to product form, cannabinoid profile, facility, ownership or licensed activity should trigger review before implementation.

Packaging and advertising show why the overlay matters. Illinois requires cannabis products to be sold in sealed, odor-proof, child-resistant containers, bars packaging images designed to appeal to minors, and bars cannabis advertising within 1,000 feet of school grounds, playgrounds and other listed places (410 ILCS 705/55-21, 410 ILCS 705/55-20). Missouri’s Constitution directs the Department to require child-resistant packaging not made to be attractive to children, and its rules set packaging, labeling and product-design standards (Mo. Const. art. XIV, sec. 2, 19 CSR 100-1.120). One brand guide serves both states only if each design element is checked against both.

The 2026 operating calendar should include legal change dates

The legal-change calendar should capture at least these 2026 dates: April 28 (Schedule III rule for FDA-approved products and state medical marijuana), June 12 (most of Public Act 104-0463 in effect), September 10 (Illinois medical opt-in opens), September 30 (Missouri emergency amendment to 19 CSR 100-1.070), November 12 (limited federal hemp phase, Illinois Hemp Act and Missouri hemp provisions begin) and December 11 (federal limitation and Missouri beverage window end under current law). Renewals, ownership approvals and local permits belong on the same calendar.

Assign each date to a named owner and a concrete deliverable. “Monitor hemp law” is not a control. “Reclassify every cannabinoid SKU under the November 12 and December 11 federal tests, the Illinois Hemp Act and Missouri House Bill 2641, with signed release or hold decisions” is, and it leaves evidence someone can review later.